Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 9, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat
Anticipated advantages of UGN-103 include a shorter manufacturing process and a simpler reconstitution procedure PRINCETON, N.J. --(BUSINESS WIRE)--Oct. 2, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat
Once issued, this patent provides U.S. intellectual property coverage of UroGen’s RTGel ® technology with medac lyophilized mitomycin formulation, covering UGN-103 and UGN-104 development programs until December 2041 PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 16, 2024-- UroGen Pharma Ltd.
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 5, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new
PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 14, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company specializing in novel therapies for urothelial and specialty cancers, today announced the successful completion of its New Drug Application (NDA) submission for investigational drug
Potential for an FDA decision as early as the first quarter of 2025, assuming priority review UGN-102 Phase 3 ENVISION trial demonstrated an unprecedented 82.3% Duration of Response at 12 Months by Kaplan-Meier analysis in LG-IR-NMIBC patients who achieved a complete response at three months Ended
Conference Call and Webcast Scheduled for Tuesday, August 13, 2024 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 5, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 17, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary
PRINCETON, N.J. , June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to
